Geographic Atrophy of the Macula

• CLINICAL_TRIALS research · 2026-02-06
  Clinical Trial Update: A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD [Phase 2]

  This document reports that GAL-101, a 2% ophthalmic solution developed by Galimedix Therapeutics, is being evaluated in a Phase 2 trial for …